Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$145.31
0.620.43%
À la fermeture: -
$145.31
0.000.00%
Après les heures de négociation: 4:00 PM EDT
Comments
Loading...
Évaluations des analystes, objectifs de prix, prévision
Biogen Inc a un objectif de cours consensus de $200.12, basé sur les évaluations des 30 analystes. Le plus élevé est de $342 attribué par HSBC le mai 3, 2024, et le plus bas est de $115 attribué par Piper Sandler le avril 29, 2025. Les 3 dernières évaluations d'analystes ont été publiées par Morgan Stanley, Jefferies et Piper Sandler le octobre 10, 2025, septembre 25, 2025 et août 14, 2025. Avec un objectif de cours moyen de $152.33 entre Morgan Stanley, Jefferies et Piper Sandler, il y a une variation implicite de 4.83% upside pour Biogen Inc à partir de ces dernières évaluations d'analystes.
Sociétés d'analyse émettant des recommandations1
Morgan Stanley
Jefferies
Piper Sandler
Citigroup
RBC Capital
1calculé à partir des notes des analystes
Notes d'analystes pour Biogen
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
10/10/2025 | 2.54% | Morgan Stanley | $144 → $149 | Maintains | Equal-Weight | |||
09/25/2025 | 30.75% | Jefferies | → $190 | Initiates | → Buy | |||
09/24/2025 | — | Needham | — | Reiterates | Hold → Hold | |||
09/04/2025 | — | Needham | — | Reiterates | Hold → Hold | |||
08/14/2025 | -18.79% | Piper Sandler | $115 → $118 | Maintains | Neutral | |||
08/01/2025 | -7.1% | Citigroup | $125 → $135 | Maintains | Neutral | |||
08/01/2025 | 50.71% | RBC Capital | $208 → $219 | Maintains | Outperform | |||
08/01/2025 | -0.9% | Morgan Stanley | $146 → $144 | Maintains | Equal-Weight | |||
08/01/2025 | 33.51% | HC Wainwright & Co. | $187 → $194 | Maintains | Buy | |||
07/07/2025 | 43.14% | RBC Capital | $213 → $208 | Maintains | Outperform | |||
06/27/2025 | 46.58% | RBC Capital | $213 → $213 | Reiterates | Outperform → Outperform | |||
06/26/2025 | 28.69% | HC Wainwright & Co. | $187 → $187 | Reiterates | Buy → Buy | |||
06/25/2025 | 46.58% | RBC Capital | $205 → $213 | Maintains | Outperform | |||
06/12/2025 | -20.86% | Piper Sandler | $115 → $115 | Reiterates | Neutral → Neutral | |||
06/12/2025 | -16.73% | Wedbush | $121 → $121 | Reiterates | Neutral → Neutral | |||
06/12/2025 | — | Needham | — | Reiterates | Hold → Hold | |||
05/07/2025 | 16.3% | Mizuho | $207 → $169 | Maintains | Outperform | |||
05/05/2025 | 20.43% | JP Morgan | $185 → $175 | Maintains | Neutral | |||
05/02/2025 | 41.08% | RBC Capital | $217 → $205 | Maintains | Outperform | |||
05/02/2025 | 51.4% | Canaccord Genuity | $265 → $220 | Maintains | Buy | |||
05/02/2025 | 28.69% | HC Wainwright & Co. | $241 → $187 | Maintains | Buy | |||
05/02/2025 | 75.49% | Baird | $300 → $255 | Maintains | Outperform | |||
05/02/2025 | — | Needham | — | Reiterates | Hold → Hold | |||
04/29/2025 | 36.95% | Truist Securities | $210 → $199 | Maintains | Buy | |||
04/29/2025 | -20.86% | Piper Sandler | $135 → $115 | Maintains | Neutral | |||
04/25/2025 | — | Needham | — | Reiterates | Hold → Hold | |||
04/23/2025 | 35.57% | Goldman Sachs | $219 → $197 | Maintains | Buy | |||
04/22/2025 | 54.84% | RBC Capital | $221 → $225 | Maintains | Outperform | |||
04/16/2025 | -16.73% | Wedbush | $135 → $121 | Maintains | Neutral | |||
04/16/2025 | — | Needham | — | Reiterates | Hold → Hold | |||
04/09/2025 | 4.6% | Morgan Stanley | $157 → $152 | Maintains | Equal-Weight | |||
04/04/2025 | — | Argus Research | — | Downgrade | Buy → Hold | |||
02/18/2025 | -7.1% | Piper Sandler | $138 → $135 | Reiterates | Neutral → Neutral | |||
02/13/2025 | 54.15% | Scotiabank | $244 → $224 | Maintains | Sector Outperform | |||
02/13/2025 | -4.34% | BMO Capital | $156 → $139 | Maintains | Market Perform | |||
02/13/2025 | 8.04% | Morgan Stanley | $192 → $157 | Maintains | Equal-Weight | |||
02/13/2025 | 68.61% | Goldman Sachs | $281 → $245 | Maintains | Buy | |||
02/13/2025 | 54.84% | RBC Capital | $231 → $225 | Maintains | Outperform | |||
02/13/2025 | -0.21% | Citigroup | $160 → $145 | Maintains | Neutral | |||
02/13/2025 | -3.65% | Wells Fargo | $165 → $140 | Maintains | Equal-Weight | |||
02/13/2025 | 65.85% | HC Wainwright & Co. | $300 → $241 | Maintains | Buy | |||
02/13/2025 | 44.52% | Truist Securities | $220 → $210 | Maintains | Buy | |||
02/13/2025 | 82.37% | Canaccord Genuity | $298 → $265 | Maintains | Buy | |||
02/13/2025 | — | Needham | — | Reiterates | Hold → Hold | |||
01/29/2025 | 7.36% | BMO Capital | $164 → $156 | Maintains | Market Perform | |||
01/28/2025 | 10.11% | Citigroup | $190 → $160 | Maintains | Neutral | |||
01/10/2025 | 13.55% | Wells Fargo | $190 → $165 | Maintains | Equal-Weight | |||
01/08/2025 | 51.4% | Truist Securities | $302 → $220 | Maintains | Buy | |||
01/02/2025 | -5.03% | Piper Sandler | $315 → $138 | Downgrade | Overweight → Neutral | |||
12/20/2024 | 12.86% | BMO Capital | $230 → $164 | Downgrade | Outperform → Market Perform | |||
12/10/2024 | 22.5% | B of A Securities | → $178 | Reinstates | → Neutral | |||
12/09/2024 | 23.87% | Jefferies | $250 → $180 | Downgrade | Buy → Hold | |||
12/05/2024 | 32.13% | Morgan Stanley | $204 → $192 | Maintains | Equal-Weight | |||
11/21/2024 | 42.45% | Mizuho | $251 → $207 | Maintains | Outperform | |||
11/18/2024 | 85.81% | Needham | $270 → $270 | Downgrade | Buy → Hold | |||
11/15/2024 | 106.46% | Baird | $294 → $300 | Maintains | Outperform | |||
11/15/2024 | — | Wolfe Research | — | Initiates | → Peer Perform | |||
11/14/2024 | 30.75% | Citigroup | → $190 | Initiates | → Neutral | |||
11/04/2024 | 44.52% | JP Morgan | $220 → $210 | Maintains | Neutral | |||
10/31/2024 | 30.75% | Wells Fargo | $225 → $190 | Maintains | Equal-Weight | |||
10/31/2024 | 75.49% | Oppenheimer | $270 → $255 | Maintains | Outperform | |||
10/31/2024 | 23.87% | Barclays | $190 → $180 | Maintains | Equal-Weight | |||
10/31/2024 | 89.25% | TD Cowen | $300 → $275 | Maintains | Buy | |||
10/31/2024 | 106.46% | HC Wainwright & Co. | $300 → $300 | Reiterates | Buy → Buy | |||
10/31/2024 | 85.81% | Needham | $270 → $270 | Reiterates | Buy → Buy | |||
10/31/2024 | 40.39% | Morgan Stanley | $285 → $204 | Downgrade | Overweight → Equal-Weight | |||
10/30/2024 | 85.81% | Needham | $270 → $270 | Reiterates | Buy → Buy | |||
10/17/2024 | 58.28% | BMO Capital | $260 → $230 | Maintains | Outperform | |||
10/10/2024 | — | Raymond James | — | Reinstates | → Market Perform | |||
10/04/2024 | 85.12% | RBC Capital | $292 → $269 | Maintains | Outperform | |||
10/03/2024 | 39.01% | UBS | $234 → $202 | Maintains | Neutral | |||
09/24/2024 | 96.13% | Needham | $285 → $285 | Reiterates | Buy → Buy | |||
09/23/2024 | 41.08% | Wedbush | $210 → $205 | Maintains | Neutral | |||
09/19/2024 | 100.95% | RBC Capital | $292 → $292 | Reiterates | Outperform → Outperform | |||
09/09/2024 | 100.95% | Cantor Fitzgerald | $292 → $292 | Reiterates | Overweight → Overweight | |||
09/04/2024 | 96.13% | Needham | $285 → $285 | Reiterates | Buy → Buy | |||
08/19/2024 | 96.13% | Needham | $285 → $285 | Reiterates | Buy → Buy | |||
08/06/2024 | 72.73% | Mizuho | $277 → $251 | Maintains | Outperform | |||
08/05/2024 | 107.83% | Truist Securities | $340 → $302 | Reiterates | Buy → Buy | |||
08/05/2024 | 96.13% | Needham | $288 → $285 | Maintains | Buy | |||
08/02/2024 | 100.95% | RBC Capital | $282 → $292 | Maintains | Outperform | |||
08/02/2024 | 54.84% | Wells Fargo | $240 → $225 | Maintains | Equal-Weight | |||
08/02/2024 | 67.92% | Scotiabank | $275 → $244 | Maintains | Sector Outperform | |||
08/02/2024 | 30.75% | Barclays | $200 → $190 | Maintains | Equal-Weight | |||
08/02/2024 | 44.52% | Wedbush | $215 → $210 | Maintains | Neutral | |||
08/01/2024 | 98.2% | Needham | $288 → $288 | Reiterates | Buy → Buy | |||
07/29/2024 | 102.33% | Baird | $316 → $294 | Maintains | Outperform | |||
07/26/2024 | 102.33% | Needham | $294 → $294 | Reiterates | Buy → Buy | |||
07/12/2024 | 115.4% | Piper Sandler | $335 → $313 | Maintains | Overweight | |||
06/28/2024 | 102.33% | Needham | $294 → $294 | Reiterates | Buy → Buy | |||
06/27/2024 | 118.15% | RBC Capital | $317 → $317 | Reiterates | Outperform → Outperform | |||
06/26/2024 | 118.15% | RBC Capital | $317 → $317 | Reiterates | Outperform → Outperform | |||
06/05/2024 | 118.15% | RBC Capital | $317 → $317 | Reiterates | Outperform → Outperform | |||
05/29/2024 | 118.15% | RBC Capital | $317 → $317 | Reiterates | Outperform → Outperform | |||
05/23/2024 | 106.46% | HC Wainwright & Co. | $300 → $300 | Reiterates | Buy → Buy | |||
05/22/2024 | 102.33% | Needham | $294 → $294 | Reiterates | Buy → Buy | |||
05/16/2024 | 133.98% | Truist Securities | $340 → $340 | Maintains | Buy | |||
05/03/2024 | 135.36% | HSBC | $339 → $342 | Maintains | Buy | |||
04/29/2024 | 85.81% | Oppenheimer | $270 → $270 | Maintains | Outperform | |||
04/25/2024 | 102.33% | Needham | $294 → $294 | Reiterates | Buy → Buy |
FAQ
Quel est le cours indicatif de l'action Biogen (BIIB) ?
Le dernier objectif de prix pour Biogen (NASDAQ:BIIB) a été rapporté par Morgan Stanley le octobre 10, 2025. Le cabinet d'analystes a fixé un objectif de prix pour $149.00 s'attendant à ce que BIIB se rise dans les 12 prochains mois (un possible changement de 2.54% upside). 68 cabinets d'analystes ont rapporté des notes au cours de la dernière année.
Quelle est la note d'analyste la plus récente pour Biogen (BIIB) ?
La dernière note d'analyste pour Biogen (NASDAQ:BIIB) a été fournie par Morgan Stanley, et Biogen maintenu leur note equal-weight.
Quand a eu lieu la dernière mise à niveau pour Biogen (BIIB) ?
Il n'y a pas de dernière amélioration pour Biogen
Quand a eu lieu la dernière dégradation pour Biogen (BIIB) ?
La dernière réduction pour Biogen Inc a eu lieu le avril 4, 2025 lorsque Argus Research a changé leur objectif de prix de N/A à N/A pour Biogen Inc.
Quand la prochaine note d'analyste sera-t-elle publiée ou mise à jour pour Biogen (BIIB) ?
Les analystes arrivent à des évaluations d'actions après avoir effectué des recherches approfondies, ce qui inclut l'examen des états financiers publics, la discussion avec les dirigeants et les clients de Biogen, et l'écoute des conférences téléphoniques sur les résultats. La plupart des analystes font cela tous les trois mois, vous devriez donc obtenir 4 notes par entreprise par société chaque année. La dernière note pour Biogen a été déposée le octobre 10, 2025, donc vous devriez vous attendre à ce que la prochaine note soit disponible vers octobre 10, 2026.
La note d'analyste pour Biogen (BIIB) est-elle correcte ?
Bien que les évaluations soient subjectives et changeront, la dernière note de Biogen (BIIB) était un maintenu avec un objectif de prix de $144.00 à $149.00. Le prix actuel de Biogen (BIIB) est de $145.31, ce qui est within la fourchette prédite par l'analyste.
Parcourir notes d'analystes et objectifs de cours sur toutes les actions.